Literature DB >> 18971951

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

R A Kyle1, S V Rajkumar.   

Abstract

New systems have emerged for diagnosis, staging and response assessment in multiple myeloma (MM). The diagnostic and response criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System is the current standard for staging of myeloma. A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies. This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM.

Entities:  

Mesh:

Year:  2008        PMID: 18971951      PMCID: PMC2627786          DOI: 10.1038/leu.2008.291

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  29 in total

1.  Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?

Authors:  Paolo G Gobbi; Luca Baldini; Chiara Broglia; Maria Goldaniga; Mario Comelli; Pierre Morel; Enrica Morra; Sergio Cortelazzo; Roberto Bettini; Giampaolo Merlini
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

2.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

3.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

4.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

5.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

6.  Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.

Authors:  R Bataille; B G Durie; J Grenier
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

7.  Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Authors:  J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

8.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

Authors:  G Tricot; B Barlogie; S Jagannath; D Bracy; S Mattox; D H Vesole; S Naucke; J R Sawyer
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

9.  Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.

Authors:  P R Greipp; J A Lust; W M O'Fallon; J A Katzmann; T E Witzig; R A Kyle
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  350 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  Novel treatment paradigm for elderly patients with multiple myeloma.

Authors:  Antonio Palumbo; Valeria Magarotto
Journal:  Am J Blood Res       Date:  2011-09-18

3.  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Authors:  Suzanne Lentzsch; Amy O'Sullivan; Ryan C Kennedy; Mohammad Abbas; Lijun Dai; Silvana Lalo Pregja; Steve Burt; Michael Boyiadzis; G David Roodman; Markus Y Mapara; Mounzer Agha; John Waas; Yongli Shuai; Daniel Normolle; Jeffrey A Zonder
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

Review 4.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

5.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

6.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.

Authors:  Francesca Gay; S Vincent Rajkumar; Morton Coleman; Shaji Kumar; Tomer Mark; Angela Dispenzieri; Roger Pearse; Morie A Gertz; John Leonard; Martha Q Lacy; Selina Chen-Kiang; Vivek Roy; David S Jayabalan; John A Lust; Thomas E Witzig; Rafael Fonseca; Robert A Kyle; Philip R Greipp; A Keith Stewart; Ruben Niesvizky
Journal:  Am J Hematol       Date:  2010-09       Impact factor: 10.047

7.  Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Authors:  S Ailawadhi; J R Mikhael; B R LaPlant; K M Laumann; S Kumar; V Roy; D Dingli; P L Bergsagel; F K Buadi; S V Rajkumar; R Fonseca; M A Gertz; P Kapoor; T Sher; S R Hayman; A K Stewart; A Dispenzieri; R A Kyle; W I Gonsalves; C B Reeder; Y Lin; R S Go; N Leung; T Kourelis; J A Lust; S J Russell; A A Chanan-Khan; M Q Lacy
Journal:  Leukemia       Date:  2017-09-01       Impact factor: 11.528

8.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

9.  MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Authors:  Anthony W Gebhard; Priyesh Jain; Rajesh R Nair; Michael F Emmons; Raul F Argilagos; John M Koomen; Mark L McLaughlin; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2013-09-18       Impact factor: 6.261

10.  Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.

Authors:  Francesca Gay; Suzanne R Hayman; Martha Q Lacy; Francis Buadi; Morie A Gertz; Shaji Kumar; Angela Dispenzieri; Joseph R Mikhael; P Leif Bergsagel; David Dingli; Craig B Reeder; John A Lust; Stephen J Russell; Vivek Roy; Steven R Zeldenrust; Thomas E Witzig; Rafael Fonseca; Robert A Kyle; Philip R Greipp; A Keith Stewart; S Vincent Rajkumar
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.